Federated Hermes, Inc. Nkarta, Inc. Transaction History

Federated Hermes, Inc.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 08, 2024	BUY	$5.27 - $10.82 $712,893 - $1.46 Million	135,274 Added 28478.74%	135,749 $802,000
Q4 2023 Jan 31, 2024	SELL	$1.31 - $6.6 $5,943 - $29,944	-4,537 Reduced 90.52%	475 $3,000
Q3 2023 Nov 13, 2023	BUY	$1.39 - $2.29 $6,530 - $10,758	4,698 Added 1496.18%	5,012 $6,000
Q2 2023 Aug 14, 2023	BUY	$2.19 - $5.17 $687 - $1,623	314 New	314 $0
Q2 2022 Aug 15, 2022	SELL	$7.77 - $19.44 $36,604 - $91,581	-4,711 Closed	0 $0
Q1 2022 May 13, 2022	BUY	$8.66 - $14.99 $35,913 - $62,163	4,147 Added 735.28%	4,711 $54,000
Q4 2021 Feb 14, 2022	BUY	$12.79 - $26.88 $7,213 - $15,160	564 New	564 $9,000

126

66.5M

173K

20K

Ticker NKTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,656,800
Market Cap $116M
Description
Nkarta, Inc., a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the sur...

Get notified when there are updates to the investment portfolio of Federated Hermes, Inc., based on Form 13F filings with the SEC.

Stay updated on Federated Hermes, Inc. with notifications on news.